Valion Bio, Inc. (VBIO) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 3, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the VBIO SEC filings page.
This page shows Valion Bio, Inc. (VBIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The latest balance sheet grew through external financing as operating losses widened and research spending became a larger cash-consuming commitment.
Total assets rose from$2.8M in FY2024 to$31.6M in FY2025. Financing cash flow reached$18.3M in FY2025 while operating cash flow remained negative, indicating that balance-sheet expansion came primarily from capital raised rather than operating earnings.
The cash pattern is less favorable than the loss line alone suggests: FY2025 net loss was
Research spending increased from
Financial Health Signals
Valion Bio, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Valion Bio, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Valion Bio, Inc. reported a net loss of $8.9M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Valion Bio, Inc. reported an operating loss of $7.9M against $146K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Valion Bio, Inc.'s EBITDA was -$6.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 261.7% from the same quarter a year earlier. Against the prior quarter it is down 7.7%.
Valion Bio, Inc. reported -$7.1M in net income in Q2 2026. This represents a decrease of 267.8% from the same quarter a year earlier. Against the prior quarter it is down 14.5%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Valion Bio, Inc. recorded an outflow of $5.3M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 191.7% from the same quarter a year earlier. Against the prior quarter it is down 6.4%.
Valion Bio, Inc. held $2.1M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Valion Bio, Inc.'s ROE was -167.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 114.9 percentage points from the same quarter a year earlier. Against the prior quarter it is down 111.2 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Valion Bio, Inc. invested $2.7M in research and development in Q2 2026. This represents an increase of 312.8% from the same quarter a year earlier. Against the prior quarter it is up 45.8%.
Valion Bio, Inc. invested $57K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 1800.0% from the same quarter a year earlier. Against the prior quarter it is up 714.3%.
Not reported for Q2 2026.
VBIO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | $146K+15.9% | $86K-38.6% | $70K-79.0% | $180K-49.6% | $126K-55.3% |
| Cost of Revenue | N/A | N/A | N/A | $291K+254.9% | $32K-70.9% | $20K-88.0% | $419K+19.0% | $82K-52.9% |
| Gross Profit | N/A | N/A | N/A | -$145K-429.5% | $54K+80.0% | $50K-70.1% | -$239K-4880.0% | $44K-59.3% |
| R&D Expenses | $2.7M+312.8% | $1.9M+453.4% | N/A | $858K+103.3% | $655K+116.9% | $335K+30.9% | $333K-7.5% | $422K+25.2% |
| SG&A Expenses | $3.7M+263.6% | $3.8M+262.8% | N/A | $1.1M+30.0% | $1.0M+30.0% | $1.0M+17.5% | $670K-41.9% | $819K-22.1% |
| Operating Income | -$6.4M-282.8% | -$5.6M-309.2% | N/A | -$2.5M-73.5% | -$1.7M-32.5% | -$1.4M+7.0% | -$298K+86.7% | -$1.4M+18.7% |
| EBITDA | -$6.1M-261.7% | -$5.6M-309.2% | N/A | -$2.5M-73.6% | -$1.7M-32.6% | -$1.4M+7.0% | -$298K+86.7% | -$1.4M+18.7% |
| Interest Expense | $691K | $648K | N/A | N/A | $0 | $0 | N/A | N/A |
| Net Income | -$7.1M-267.8% | -$6.2M-312.9% | N/A | -$2.6M-81.4% | -$1.9M-52.5% | -$1.5M-1.4% | -$1.5M+34.2% | -$1.4M+18.7% |
| EPS (Basic) | -$2.17+0.9% | -$2.23+11.5% | -$1.35+92.7% | -$1.97+49.9% | -$2.19+59.2% | -$2.52+85.3% | -$18.61+88.8% | -$3.93-165.5% |
| EPS (Diluted) | N/A | N/A | N/A | N/A | -$2.19 | -$2.52 | -$18.61 | -$0.23 |
| Diluted Shares (Avg) | N/A | N/A | N/A | N/A | 881,294 | 596,368 | N/A | 6M |
Not reported in any period shown, so not listed: Income Tax.
VBIO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $32.5M+620.3% | $38.2M+911.8% | $31.6M+1026.0% | $6.2M+83.5% | $4.5M-5.7% | $3.8M+14.9% | $2.8M-45.6% | $3.4M-51.6% |
| Current Assets | $3.4M+83.6% | $8.7M+586.1% | $13.0M+392.8% | $3.7M+18.2% | $1.8M-60.5% | $1.3M-55.4% | $2.6M-43.3% | $3.2M-51.0% |
| Cash & Equivalents | $2.1M+78.0% | $7.2M+978.5% | $12.6M+531.6% | $3.5M+57.6% | $1.2M-67.9% | $669K-59.9% | $2.0M-41.0% | $2.2M-57.7% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $750K+165.0% | $750K+145.1% | $0-100.0% | $4K-99.5% | $283K-63.1% | $306K-60.5% | $319K-57.8% | $731K-21.2% |
| Accounts Receivable | N/A | N/A | N/A | $19K+111.1% | $13K-18.8% | $13K-82.4% | $69K-60.3% | $9K-93.1% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $3.5M | $3.5M | $3.5M | N/A | N/A | N/A | $0 | N/A |
| Total Liabilities | $28.2M+3338.1% | $19.7M+2554.1% | $14.8M+5344.9% | $2.8M+402.7% | $821K+38.9% | $741K-34.6% | $272K-82.8% | $560K-54.9% |
| Current Liabilities | $3.0M+271.0% | $2.6M+252.9% | $646K+137.5% | $638K+13.9% | $821K+38.9% | $741K-25.3% | $272K-80.6% | $560K-44.0% |
| Non-Current Liabilities | $25.2M | $17.1M | $14.2M | $2.2M | $0 | $0-100.0% | $0-100.0% | $0-100.0% |
| Total Equity | $4.2M+15.2% | $11.1M+264.4% | $16.8M+562.6% | $3.4M+20.5% | $3.7M-12.0% | $3.0M+41.0% | $2.5M-29.2% | $2.8M-50.8% |
| Retained Earnings | -$66.5M-41.6% | -$59.0M-31.1% | -$52.6M-20.8% | -$49.6M-18.0% | -$47.0M-15.6% | -$45.0M-14.4% | -$43.5M-14.9% | -$42.1M-18.0% |
Not reported in any period shown, so not listed: Long-Term Debt.
VBIO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.3M-189.1% | -$5.0M-463.7% | -$2.3M-67.5% | -$2.0M-41.9% | -$1.8M-42.0% | -$889K+46.6% | -$1.4M+23.1% | -$1.4M+24.8% |
| Depreciation & Amortization | $358K+35700.0% | $4K+300.0% | $3K | $0-100.0% | $1K0.0% | $1K0.0% | $0-100.0% | $1K0.0% |
| Stock-Based Compensation | $133K-24.9% | $208K+108.0% | N/A | $138K+137.9% | $177K+227.8% | $100K+85.2% | N/A | $58K+20.8% |
| Capital Expenditures | $57K+1800.0% | $7K | $25K | $10K | $3K | $0 | $0 | N/A |
| Free Cash Flow | -$5.3M-191.7% | -$5.0M-464.5% | -$2.3M-69.4% | -$2.0M | -$1.8M | -$889K | -$1.4M+23.1% | N/A |
| Investing Cash Flow | -$57K-185.0% | -$7K+98.7% | -$149K | -$10K | -$20K | -$526K | $0 | N/A |
| Financing Cash Flow | $231K-90.2% | -$44K-153.7% | $11.6M+887.4% | $4.3M+4504.1% | $2.4M-28.7% | $82K+234.4% | $1.2M | -$97K-102.2% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
VBIO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | -99.3%-134.2pp | 62.8%+41.4pp | 71.4%+21.4pp | -132.8% | 34.9%-3.4pp |
| Operating Margin | N/A | N/A | N/A | -1700.7% | -1951.2% | -1967.1% | -165.6% | -1135.7% |
| Net Margin | N/A | N/A | N/A | -1778.1% | -2245.3% | -2145.7% | -820.6% | -1135.7% |
| Return on Equity | -167.3%-114.9pp | -56.1%-6.6pp | N/A | -76.0%-25.5pp | -52.4%-22.2pp | -49.5%+19.3pp | -58.3%+4.4pp | -50.5%-20.0pp |
| Return on Assets | -21.9%+21.0pp | -16.2%+23.5pp | N/A | -41.7%+0.5pp | -42.8%-16.4pp | -39.8%+5.3pp | -52.6%-9.1pp | -42.2%-17.0pp |
| Current Ratio | 1.11-1.1x | 3.31+1.6x | 20.13+10.4x | 5.86+0.2x | 2.24-5.6x | 1.70-1.1x | 9.70+6.4x | 5.65-0.8x |
| Debt-to-Equity | 6.65+6.4x | 1.78+1.5x | 0.88+0.8x | 0.82+0.6x | 0.22+0.1x | 0.24-0.3x | 0.11-0.3x | 0.200.0x |
| Asset Turnover | N/A | N/A | N/A | 0.020.0x | 0.020.0x | 0.02-0.1x | 0.060.0x | 0.040.0x |
| FCF Margin | N/A | N/A | N/A | -1374.0% | -2127.9% | -1270.0% | -758.3% | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Gross Margin, Operating Margin, Net Margin, FCF Margin.
Where Valion Bio, Inc. Ranks
Frequently Asked Questions
Is Valion Bio, Inc. profitable?
No, Valion Bio, Inc. (VBIO) reported a net income of -$8.9M in fiscal year 2025.
What is Valion Bio, Inc.'s EBITDA?
Valion Bio, Inc. (VBIO) had EBITDA of -$7.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Valion Bio, Inc.'s return on equity (ROE)?
Valion Bio, Inc. (VBIO) has a return on equity of -52.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Valion Bio, Inc.'s free cash flow?
Valion Bio, Inc. (VBIO) recorded an outflow of $7.0M in free cash flow during fiscal year 2025. This represents a -22.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Valion Bio, Inc.'s operating cash flow?
Valion Bio, Inc. (VBIO) recorded an outflow of $7.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Valion Bio, Inc.'s total assets?
Valion Bio, Inc. (VBIO) had $31.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Valion Bio, Inc.'s capital expenditures?
Valion Bio, Inc. (VBIO) invested $38K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Valion Bio, Inc. spend on research and development?
Valion Bio, Inc. (VBIO) invested $3.1M in research and development during fiscal year 2025.
What is Valion Bio, Inc.'s current ratio?
Valion Bio, Inc. (VBIO) had a current ratio of 20.13 as of fiscal year 2025, which is generally considered healthy.
What is Valion Bio, Inc.'s debt-to-equity ratio?
Valion Bio, Inc. (VBIO) had a debt-to-equity ratio of 0.88 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Valion Bio, Inc.'s return on assets (ROA)?
Valion Bio, Inc. (VBIO) had a return on assets of -28.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Valion Bio, Inc.'s P/E ratio?
Valion Bio, Inc. (VBIO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $2.3M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Valion Bio, Inc.'s price-to-sales ratio?
Valion Bio, Inc. (VBIO) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $2.3M as of Oct 3, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Valion Bio, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Valion Bio, Inc. (VBIO) held $12.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.0M over that year. Dividing the one by the other, the reported balance equals about 22 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Valion Bio, Inc.'s Piotroski F-Score?
Valion Bio, Inc. (VBIO) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Valion Bio, Inc.'s earnings high quality?
Valion Bio, Inc. (VBIO) reported a net loss of $8.9M while operations used $7.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Valion Bio, Inc. cover its interest payments?
Valion Bio, Inc. (VBIO) reported an operating loss of $7.9M against $146K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.